Enterprise Value

8.649B

Cash

399.4M

Avg Qtr Burn

-116.8M

Short % of Float

5.24%

Insider Ownership

0.76%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
SKYTROFA (TransCon hGH) (lonapegsomatropin) Details
Pediatric growth hormone deficiency

Approved

Quarterly sales

YORVIPATH® (palopegteriparatide, developed as TransCon PTH) Details
Adult hypoparathyroidism

Big Mover™

Susp. Mover™

PDUFA

Approval decision

TransCon hGH Details
Adult growth hormone deficiency

BLA

Submission

TransCon CNP Details
Achondroplasia

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

TransCon hGH Details
Turner syndrome

Phase 2

Data readout

TransCon IL-2 B/y Details
Cancer, Solid tumor/s

Phase 2

Data readout

Phase 2

Data readout

TransCon CNP Details
Achondroplasia

Phase 2

Data readout